Evidence map›Paper›PMID 33920339›Full record

ArticleLife (Basel, Switzerland)2021

Generation of Antibodies against Foot-and-Mouth-Disease Virus Capsid Protein VP4 Using Hepatitis B Core VLPs as a Scaffold.

Jessica Swanson, Rennos Fragkoudis, Philippa C Hawes, Joseph Newman, Alison Burman, Anusha Panjwani, Nicola J Stonehouse, Tobias J Tuthill

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jessica SwansonThe Pirbright Institute, Pirbright GU24 0NF, UK.
Rennos FragkoudisThe Pirbright Institute, Pirbright GU24 0NF, UK.
Philippa C HawesThe Pirbright Institute, Pirbright GU24 0NF, UK.ORCID 0000-0003-4665-9663
Joseph NewmanThe Pirbright Institute, Pirbright GU24 0NF, UK.ORCID 0000-0003-0717-8672
Alison BurmanThe Pirbright Institute, Pirbright GU24 0NF, UK.
Anusha PanjwaniThe Pirbright Institute, Pirbright GU24 0NF, UK.
Nicola J StonehouseFaculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK.ORCID 0000-0003-1146-5519
Tobias J TuthillThe Pirbright Institute, Pirbright GU24 0NF, UK.
The Pirbright Institute · GBUniversity of Leeds · GB

Funding

Biotechnology and Biological Sciences Research Council BBS/E/I/00001989, BBS/E/I/00007034, BBS/E/I/00007037, BBS/E/I/00007038, BBS/E/I/00007039Biotechnology and Biological Sciences Research Council BBS/E/I/00007034Biotechnology and Biological Sciences Research Council BBS/E/I/00007038
6 · The paper itself

Abstract

The picornavirus foot-and-mouth disease virus (FMDV) is the causative agent of the economically important disease of livestock, foot-and-mouth disease (FMD). VP4 is a highly conserved capsid protein, which is important during virus entry. Previous published work has shown that antibodies targeting the N-terminus of VP4 of the picornavirus human rhinovirus are broadly neutralising. In addition, previous studies showed that immunisation with the N-terminal 20 amino acids of enterovirus A71 VP4 displayed on the hepatitis B core (HBc) virus-like particles (VLP) can induce cross-genotype neutralisation. To investigate if a similar neutralising response against FMDV VP4 could be generated, HBc VLPs displaying the N-terminus of FMDV VP4 were designed. The N-terminal 15 amino acids of FMDV VP4 was inserted into the major immunodominant region. HBc VLPs were also decorated with peptides of the N-terminus of FMDV VP4 attached using a HBc-spike binding tag. Both types of VLPs were used to immunise mice and the resulting serum was investigated for VP4-specific antibodies. The VLP with VP4 inserted into the spike, induced VP4-specific antibodies, however the VLPs with peptides attached to the spikes did not. The VP4-specific antibodies could recognise native FMDV, but virus neutralisation was not demonstrated. This work shows that the HBc VLP presents a useful tool for the presentation of FMDV capsid epitopes.

Indexed as

antibodiescapsidFMDVpicornavirusVLP

Identifiers

PMID33920339
PMCPMC8069431
OpenAlexW3155654913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.